Title: Cardiotoxicity of Anthracyclines and Trastuzimab for HER 2+ Breast Cancer Patients

Date: June 06, 2007

Research question:
What is the risk for cardiotoxicity for her2+ breast cancer patients on anthracyclines or anthracyclines and herceptin?

Methods:
A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 2, 2007), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI, EuroScan, international HTA agencies, and a focused Internet search. Results include articles published between 2002 and the present, and are limited to English language publications only. Internet links are provided, where available.

Results:

Health technology assessments:
None found

Systematic reviews:
None found

Randomized controlled trials:


Prepared by: Kristen Moulton, B.A., Research Assistant
Amanda Hodgson, M.L.I.S., Information Specialist
Health Technology Inquiry Service
Email: htis@cadth.ca
Tel: 1-866-898-8439
Appendix – Further information:

Clinical studies:


Review articles:


Additional references: